fosaprepitant / Generic mfg. - LARVOL DELTA

An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC (clinicaltrials.gov) - P4 | N=200 | Not yet recruiting | Sponsor: Shanghai 6th People's Hospital

New P4 trial • Chemotherapy-Induced Nausea and Vomiting

Novel inhibitors of BCRP and P-gp found among drugs used in the treatment of cancer (AACR 2026) - "Of the investigated compounds, cabozantinib (IC50 of 0.65 µM), midostaurin (0.69 µM), and entrectinib (5.8 µM) showed the strongest inhibition of BCRP. Nilotinib (1.0 µM), osimertinib (2.0 µM), and abemaciclib (2.4 µM) showed the strongest inhibition of the P-gp. The highest I2/IC50 ratios for BCRP were observed for mitotane (6190), cabozantinib (1730), and abiraterone (831). For P-gp, the highest I2/IC50 ratios were observed for nilotinib (2880), pazopanib (1580), and mitotane (1480)...The highest I1/IC50 ratios for BCRP were observed for doxorubicin (8.2), etoposide (2.8), and fosaprepitant (0.84). For P-gp, the highest I1/IC50 ratios were observed for amscarine (1.6), vinorelbine (0.55), and fosaprepitant (0.50)...Mechanistic static model for BCRP inhibitors suggested that cabozantinib, midostaurin, and apalutamide could almost fully inhibit intestinal BCRP, increasing the exposure to concomitantly administered rosuvastatin by 94%, 89%,..."

Breast Cancer • Oncology • Solid Tumor

Comparison of Intraoperative Antiemetics for Pediatric Chiari Decompression (SCCM 2026) - "Aprepitant, whether used alone or in combination with ondansetron and/or dexamethasone, has been shown to outperform ondansetron for PONV...We hypothesized that patients who received intraoperative fosaprepitant (F) or aprepitant (A) would have decreased PONV and pain without significant difference in length of stay (LOS) compared to other perioperative antiemetic regimens. We performed a retrospective chart review of all patients who were admitted for and underwent FMD for Chiari malformation September 2014 through August 2024 at a quaternary pediatric hospital... Patients who received intraoperative F/A compared to those who did not had decreased odds of significant post-operative emesis. We discovered heterogeneity in post-operative pharmacotherapy regimens that may contribute to the lack of effect on pain. The standard addition of F/A to intraoperative care for FMD should be considered especially for patients at higher risk of PONV."

Clinical • Pediatrics

Fosaprepitant versus Ondansetron for Preventing Postoperative Nausea and Vomiting After Video-Assisted Thoracoscopic Lung Resection: A Randomized Controlled Clinical Trial. (PubMed, Drug Des Devel Ther) - P=N/A | "In this prospective, double-blind, randomized controlled clinical trial, 233 adults aged 18-70 years undergoing elective video-assisted thoracoscopic lung resection with an Apfel score ≥ 2 were randomized 1:1 to receive intravenous fosaprepitant 150 mg or ondansetron 8 mg, each combined with dexamethasone 5 mg. Fosaprepitant was superior to ondansetron in preventing early postoperative vomiting and delayed-phase PONV, and it represents an effective antiemetic strategy for high-risk thoracic surgical patients. Registration number, NCT05881486; https://clinicaltrials.gov."

Clinical • Journal • Video

Intravenous Fosaprepitant Versus Oral Aprepitant for Children Receiving Highly Emetogenic Chemotherapy: An Investigator-Initiated Randomized, Open-Label, Non-Inferiority Trial. (PubMed, Pediatr Blood Cancer) - "Non-inferiority of fosaprepitant compared to aprepitant was not demonstrated in children undergoing their first cycle of HEC."

Head-to-Head • Journal • Chemotherapy-Induced Nausea and Vomiting

Palpitant-study: Postoperative recovery with the addition of long-acting NK1- and 5-HT3 receptor antagonists as prophylaxis for post-operative nausea and vomiting. A prospective, double-blind, randomized trial in laparoscopic surgery. (clinicaltrialsregister.eu) - P2/3 | N=220 | Not yet recruiting | Sponsor: Region Vaesternorrland, Umea University

New P2/3 trial

Optimizing Antiemetic Strategies Across Phases of Chemotherapy-Induced Nausea and Vomiting: Real-World Evidence in Breast Cancer. (PubMed, Curr Oncol) - "This real-world analysis demonstrates that antiemetic effectiveness varies by CINV phase, even within a relatively homogeneous, high-risk patient cohort. The results highlight the importance of phase-tailored prophylactic strategies to optimize symptom control and improve patient quality of life in highly emetogenic chemotherapy settings."

CINV • HEOR • Journal • Real-world evidence • Breast Cancer • Chemotherapy-Induced Nausea and Vomiting • Oncology • Solid Tumor

Cyclic vomiting syndrome. (PubMed, Brain Dev) - "The NASPGHAN 2025 guidelines for the management of CVS in children recommend non-steroidal anti-inflammatory drugs, triptans, ondansetron, aprepitant, and fosaprepitant for acute medicine...The recommended medications include propranolol, cyproheptadine, aprepitant, and amitriptyline. The guidelines also recommend not using the antiseizure medications topiramate and valproic acid. However, antiseizure medications are recommended only for patients who are unresponsive to the aforementioned preventive medications and who have frequent vomiting and severe symptoms."

Journal • Review • CNS Disorders • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Hepatology • Migraine • Pain • Pediatrics • Rare Diseases

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen (clinicaltrials.gov) - P3 | N=92 | Recruiting | Sponsor: The Affiliated People's Hospital of Ningbo University

New P3 trial • Bone Marrow Transplantation • Chemotherapy-Induced Nausea and Vomiting • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer (clinicaltrials.gov) - P3 | N=388 | Recruiting | Sponsor: Jiuda Zhao | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Oncology • Solid Tumor

Retrospective Analysis of Intravenous Fosaprepitant-Associated Hypersensitivity Reactions in Pediatric Patients Following Administration Changes (ASHP 2025) - No abstract available

Retrospective data • Immunology • Pediatrics

Effect of Fosaprepitant on Busulfan AUC on BMT Patients (ASHP 2025) - "Hosted by the Section of Clinical Specialists and Scientists"

Clinical • Pediatrics

A novel Ondansetron extended release injectable suspension (OERIS): evaluation of Safety, tolerability and pharmacokinetics in a phase I trial. (PubMed, Cancer Chemother Pharmacol) - "OERIS is a promising, convenient, safe anti-emetic therapy effective for acute and delayed phases (lasts for 5-days) of CINV in patients receiving chemotherapy with a single dose."

Journal • P1 data • PK/PD data • Chemotherapy-Induced Nausea and Vomiting • Oncology

QLM2010-301: To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy. (clinicaltrials.gov) - P3 | N=665 | Completed | Sponsor: Qilu Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Mar 2026 ➔ Oct 2025 | Trial primary completion date: Dec 2025 ➔ Aug 2025

Trial completion • Trial completion date • Trial primary completion date • Chemotherapy-Induced Nausea and Vomiting

CINV GUIDELINE CONCORDANT CARE: HIGH DOSE METHOTREXATE (SIOP 2025) - "The most frequent antiemetics prescribed included aprepitant, fosaprepitant, ondansetron and palonosetron. Guideline concordant care is fundamental to optimising antiemetic prophylaxis, promoting a standardised prescribing approach that aligns with the emetic potential of the chemotherapy to ultimately improve quality of life."

CINV • Discordant • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Chemotherapy-Induced Nausea and Vomiting • Hematological Malignancies • Leukemia • Lymphoma • Pediatrics • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma • T-cell Acute Lymphoblastic Lymphoma

Aprepitant and fosaprepitant as a prophylactic antiemetic for preventing postoperative nausea and vomiting after general anaesthesia: a systematic review and meta-analysis. (PubMed, Clinics (Sao Paulo)) - "Aprepitant reduces the incidence of postoperative nausea, vomiting and the use of rescue antiemetics and increases the complete response rate among adult patients from 0 to 24 hours after surgery. Fosaprepitant reduces the incidence of vomiting from 0 to 24 hours after surgery. Findings primarily reflect female patients; male applicability requires further study."

Journal • Retrospective data • Review • Anesthesia

Prevention of Postoperative Nausea and Vomiting with Intravenous Fosaprepitant in Patients Undergoing Bariatric Surgery (ASA 2025) - "Our findings revealed that the incidence of postoperative nausea in patients who received fosaprepitant was significantly lower compared to patients who received ondansetron and dexamethasone alone (17.7% vs. 39.7%, p<0.0001). Therefore, fosaprepitant may indirectly reduce the risk of QT-prolongation and related side effects, since patients would no longer require as many rescue doses. Future prospective, randomized controlled trials that further explore the efficacy of fosaprepitant in prevention of PONV and its influence on related outcomes, such as hospital readmissions and patient satisfaction, are warranted."

Bariatric surgery • Clinical • Surgery • Anesthesia

Breast Cancer‒Associated Allergy Caused by Fosnetupitant-A Report of Four Cases (PubMed, Gan To Kagaku Ryoho) - "We describe the cases of 4 patients with breast cancer who developed an allergy to fosnetupitant (Pro‒NETU). The patients in cases 2, 3, and 4 had known allergies to docetaxel, and the cause of allergy in case 4 was unknown. Polysorbate 80, contained in docetaxel, fosaprepitant, and Pro‒NETU, was suspected to be the cause of allergy in cases 1, 2, and 3."

Journal • Allergy • Breast Cancer • Cardiovascular • Immunology • Oncology • Pulmonary Disease • Solid Tumor

Fosaprepitant Dimeglumine Alleviates Dengue Virus Infection and Virus-Induced Inflammatory Responses. (PubMed, ACS Infect Dis) - "For the first time, we report that fosaprepitant dimeglumine significantly suppressed the levels of the proinflammatory cytokines IL-6 and IP-10 in differentiated THP-1 macrophages infected with DENV-2. Fosaprepitant dimeglumine not only effectively inhibits DENV replication but also attenuates virus-induced inflammatory responses, which makes it a promising candidate for drug repurposing in the treatment of severe dengue."

Journal • Dengue Fever • Infectious Disease • Inflammation • IFNG • IL6

Cannabinoid Hyperemesis Syndrome Treated With Fosaprepitant: A Case Report. (PubMed, Cureus) - "The usual treatment options for nausea and vomiting include fluids and a combination of metoclopramide, ondansetron, promethazine, or prochlorperazine. We present a case where fosaprepitant was utilized for intractable nausea and vomiting when other treatment modalities failed for CHS."

Journal

Antiemetic drug fosaprepitant exerts anti-tumor effects against NSCLC by targeting FAK to inhibit AKT and JNK/c-Jun pathways. (PubMed, Acta Pharmacol Sin) - "Collectively, FOS exhibits significant anti-NSCLC activity both in vitro and in vivo by binding to FAK and inhibiting its phosphorylation, thereby blocking the AKT and JNK/c-Jun signaling pathways. These results suggest FOS as a novel FAK inhibitor for NSCLC treatment."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BARF RCT: Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide (clinicaltrials.gov) - P4 | N=212 | Not yet recruiting | Sponsor: Montefiore Medical Center | Initiation date: Jun 2025 ➔ May 2026 | Trial primary completion date: Mar 2026 ➔ Feb 2027 | Phase classification: P2/3 ➔ P4 | Trial completion date: Mar 2026 ➔ Feb 2027

Phase classification • Trial completion date • Trial initiation date • Trial primary completion date

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting (clinicaltrials.gov) - P2/3 | N=250 | Recruiting | Sponsor: Montefiore Medical Center | Trial completion date: May 2025 ➔ Jun 2026 | Trial primary completion date: May 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date

Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting (clinicaltrials.gov) - P3 | N=126 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Xinxiang Medical College

New P3 trial • Chemotherapy-Induced Nausea and Vomiting • Solid Tumor

Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting. (PubMed, Future Oncol) - "This individual patient data (IPD) meta-analysis compared the efficacy of NEPA (netupitant/fosnetupitant) and aprepitant/fosaprepitant-based regimens in preventing chemotherapy-induced nausea and vomiting (CINV)...A total of six studies involving 2,767 patients were included evaluating NEPA plus dexamethasone versus aprepitant/fosaprepitant plus any 5-HT3RA plus dexamethasone for patients with cancer receiving HEC/MEC. Complete response and no significant nausea rates were similar during the acute (0-24 h) phase but NEPA showed significantly higher rates than aprepitant during the delayed ( > 24-120 h) and overall (0-120 h) phases and on Days 3-5 following chemotherapy. Improved CINV prevention was observed with NEPA-based regimens, particularly during Days 3-5, highlighting its potential for managing prolonged nausea and vomiting associated with emerging anticancer targeted therapies."

CINV • Journal • Retrospective data • Review • Chemotherapy-Induced Nausea and Vomiting • Oncology